GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (CHIX:SOBIs) » Definitions » Market Cap

Swedish Orphan Biovitrum AB (CHIX:SOBIS) Market Cap : kr107,978 Mil (As of Dec. 11, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Swedish Orphan Biovitrum AB Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Swedish Orphan Biovitrum AB's share price for the quarter that ended in Sep. 2024 was kr323.6. Swedish Orphan Biovitrum AB's Shares Outstanding (EOP) for the quarter that ended in Sep. 2024 was 343 Mil. Therefore, Swedish Orphan Biovitrum AB's market cap for the quarter that ended in Sep. 2024 was kr111,136 Mil.

Swedish Orphan Biovitrum AB's quarterly market cap increased from Mar. 2024 (kr90,031 Mil) to Jun. 2024 (kr95,770 Mil) and increased from Jun. 2024 (kr95,770 Mil) to Sep. 2024 (kr111,136 Mil).

Swedish Orphan Biovitrum AB's annual market cap increased from Dec. 2021 (kr57,242 Mil) to Dec. 2022 (kr69,017 Mil) and increased from Dec. 2022 (kr69,017 Mil) to Dec. 2023 (kr83,512 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Swedish Orphan Biovitrum AB's Enterprise Value for Today is kr125,251 Mil.


Swedish Orphan Biovitrum AB Market Cap Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Market Cap Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 47,541.68 51,327.53 57,241.51 69,016.51 83,512.27

Swedish Orphan Biovitrum AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 74,337.14 83,512.27 90,031.03 95,770.27 111,135.89

Competitive Comparison of Swedish Orphan Biovitrum AB's Market Cap

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB's Market Cap Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Market Cap distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Market Cap falls into.



Swedish Orphan Biovitrum AB Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Swedish Orphan Biovitrum AB's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=kr245.8*339.757
=kr83,512

Swedish Orphan Biovitrum AB's Market Cap for the quarter that ended in Sep. 2024 is calculated as

Market Cap (Q: Sep. 2024 )=Share Price (Q: Sep. 2024 )*Shares Outstanding (EOP) (Q: Sep. 2024 )
=kr323.6*343.436
=kr111,136

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Swedish Orphan Biovitrum AB  (CHIX:SOBIs) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Swedish Orphan Biovitrum AB Market Cap Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Swedish Orphan Biovitrum AB Business Description

Traded in Other Exchanges
Address
Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Swedish Orphan Biovitrum AB Headlines

No Headlines